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Abstract
A variety of internal and external factors such as exercise, nutrition, inflammation, 
and cancer‐associated cachexia affect the regulation of skeletal muscle mass. Because 
skeletal muscle functions as a crucial regulator of whole body metabolism, rather 
than just as a motor for locomotion, the enhancement and maintenance of muscle 
mass and function are required to maintain health and reduce the morbidity and mor-
tality associated with diseases involving muscle wasting. Recent studies in this field 
have made tremendous progress; therefore, identification of the mechanisms that 
regulate skeletal muscle mass is necessary for the physical and nutritional manage-
ment of both athletes and patients with muscle wasting disease. In this review, we 
present an overall picture of the interactions regulating skeletal muscle mass, particu-
larly focusing on the insulin‐like growth factor‐I (IGF‐I)/insulin‐Akt‐mammalian 
target of rapamycin (mTOR) pathway, skeletal muscle inactivity, and endurance and 
resistance exercise. We also discuss the contribution of nitric oxide (NO) to the regu-
lation of skeletal muscle mass based on the current knowledge of the novel role of 
NO in these processes.
K E Y W O R D S
fork head box O (FoxO), mammalian target of rapamycin (mTOR), nitric oxide synthase (NOS), reactive 
oxygen species (ROS), ubiquitin proteasome system (UPS)
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1 |  BACKGROUND
Increasing muscle strength and maintaining muscle mass and 
function are necessary not only for athletes but also for aging 
people; rather than just as a motor for locomotion, skeletal 
muscle functions as a crucial regulator of whole body me-
tabolism.1,2 Systemic wasting conditions cause the rapid loss 
of muscle mass, weakness, and increased disability, conse-
quently reducing the quality of life, and are directly linked 
to mortality.3 Recent research in this field has made tremen-
dous progress4; identification of the mechanisms that reg-
ulate skeletal muscle mass is required for the physical and 
nutritional management of athletes and patients with muscle 
wasting.
Reactive oxygen species (ROS)‐ and reactive nitrogen 
species (RNS)‐mediated signaling processes are very im-
portant in the maintenance of skeletal muscle mass. ROS/
RNS are endogenously generated from superoxide and nitric 
oxide (NO), respectively, at low levels under resting condi-
tions, which become elevated during skeletal muscle con-
traction.5 While they affect the physiological functions of 
myofilaments, the sarcoplasmic reticulum (SR), and other 
cellular proteins and structures via redox‐mediated signaling 
pathways, a non‐physiological increase in ROS/RNS causes 
an imbalance between skeletal muscle protein synthesis and 
degradation, leading to muscle atrophy.6 A variety of factors 
beneficially or harmfully affect skeletal muscle mass though 
ROS/RNS‐mediated mechanisms. Therefore, increasing at-
tention has been paid to NO‐mediated regulation of skeletal 
muscle mass in health and disease.7,8
In this short review, we give an overall description of the 
interactions between the factors regulating skeletal muscle 
mass and muscle atrophy/hypertrophy, particularly focusing 
on the insulin‐like growth factor‐I (IGF‐I)/insulin‐Akt‐mam-
malian target of rapamycin (mTOR) pathway, skeletal muscle 
inactivity, and exercise. We also discuss the NO contribution 
to the regulation of skeletal muscle mass by presenting the 
current knowledge on the novel roles of NO in this research 
field.
2 |  FACTORS REGULATING 
SKELETAL MUSCLE MASS: THE 
OVERALL PICTURE
A variety of internal and external stimuli ranging from exer-
cise training to prolonged bed rest and cancer‐associated ca-
chexia, affect the regulation of skeletal muscle mass (Figure 
1). Although the signaling pathways regulating skeletal 
muscle mass are complicatedly intertwined, IGF‐I/insulin 
F I G U R E  1  Overall scheme of the factors regulating skeletal muscle mass. The factors regulating skeletal muscle mass. There are three 
outcomes resulting from skeletal muscle regulation; mitochondriogenesis, hypertrophy, and atrophy. ATII, angiotensin II; FoxO, Fork head box O; 
IGF‐Ⅰ, insulin growth factor‐I; mTOR, mammalian target of rapamycin; NADPH oxidase, nicotinamide adenine dinucleotide phosphate oxidase; 
NFkB, nuclear factor kappa B; PGC‐1α1, peroxisome proliferator‐activated receptor gamma coactivator‐1α1; PI3K, phosphoinositide 3‐kinase; 
ROS, reactive oxygen species; TFEB, transcription factor EB; TNFα, tumor necrosis factor α; UPS, ubiquitin proteasome system
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signaling is a main trigger controlling skeletal muscle protein 
balance not only by interacting with protein kinases such as 
Akt and its downstream effectors, mTOR and transcription 
factor EB (TFEB), but also by being affected by exercise, 
myostatin, and anabolic hormones.
As aging progresses, protein synthesis in skeletal mus-
cle declines (called sarcopenia), partly due to a reduction 
in the levels of anabolic hormones such as androgen (tes-
tosterone), growth hormone, and IGF‐I.4 Particularly in 
males, the reduced production and bioavailability of andro-
gens during aging directly contributes to muscle atrophy 
because androgens play a major role in the maintenance 
and restoration of muscle mass by stimulating the upstream 
pathway of mTOR (Figure 1).9 Angiotensin II (ATII) is a 
main effector molecule of the renin‐angiotensin system, 
which physiologically maintains the sodium and water 
balance. In congestive heart failure, ATII increases ROS 
production in skeletal muscle via the angiotensin II type 
1 receptor (AT1R) and NADPH oxidase‐dependent mech-
anism, which subsequently induces proteolytic enzymes 
leading to muscle protein degradation, and also inhibits 
the IGF‐I/insulin‐Akt‐mTOR pathway by phosphorylation 
of serine residues on the insulin receptor substrate (IRS) 
(Figure 1).10 Glucocorticoids inhibit IGF‐I‐mediated mus-
cle growth; they stimulate myostatin expression resulting 
in the downregulation of protein synthesis as well as the 
proliferation and differentiation of muscle satellite cells 
(Figure 1).11 Inflammatory cytokines, particularly tumor 
necrosis factor α (TNFα), activate the transcription factor 
NF‐κB expressed in skeletal muscle through the activation 
of IκB kinase (IKKβ), which phosphorylates IκB, leading 
to the nuclear translocation of NF‐κB and activation of NF‐
κB‐mediated gene transcription, including genes that regu-
late the ubiquitin proteasome system (UPS) (Figure 1).12,13
The above mentioned diverse catabolic stimuli, followed 
by the activation of key transcription factors, fork head box O 
(FoxO) and NFκB, and proteolytic enzymes such as calpains 
and caspases, result in skeletal muscle atrophy. However, the 
responses following these catabolic stimuli all share a set of 
common downstream transcriptional pathways leading to 
increased protein degradation and reduced protein synthe-
sis (Figure 1). Microarray studies identified atrophy‐related 
genes (atrogenes) that are induced or repressed in various 
wasting conditions. Among these genes are those encod-
ing several E3 ubiquitin ligases such as muscle ring finger 
1 (MURF1) and muscle atrophy F box (MAFbx, also called 
atrogin1), which mark the target proteins by ubiquitination, 
and form the UPS to degrade myofibrillar proteins by the 
26S proteasome.14 However, oxidized proteins induced by 
ROS (eg in heart failure) are degraded by the 20S proteasome 
without prior ubiquitination (Figure 2).15 The detailed mech-
anisms of how the UPS removes short‐living proteins can 
be found elsewhere.16 In contrast, the autophagy‐lysosomal 
system (ALS) is a proteolytic system that removes long‐liv-
ing proteins such as defunct organelles and mitochondria.17,18 
The activated caspases and calpains also degrade muscle pro-
teins directly or through the upstream UPS and ALS (Figure 
2). In these processes, UPS causes reduced muscle strength 
through the degradation of myofibrillar proteins in the con-
tractile machinery, and ALS causes reduced endurance ca-
pacity through degradation of the mitochondria and other 
organelles.4
Recent accumulating evidence has also shown a coordi-
nated interaction of muscle atrophy with endoplasmic reticu-
lum (ER) stress and the subsequent unfolded protein response 
(UPR).19 The ER orchestrates the synthesis, folding, and 
structural maturation of cellular proteins. However, aging, 
exercise, starvation, cancer cachexia, denervation, high fat 
diet, and many other perturbations disrupt cell homeostasis 
leading to ER stress. The ER deals with such stresses through 
initiating UPR, which properly folds the unfolded and mis-
folded proteins to control protein quality.20 In these pro-
cesses, a physiological range of ER stress protects the muscle 
from undergoing further damage by inducing ER chaperone 
proteins. On the other hand, high levels of ER stress, such 
as cancer and heart failure‐associated cachexia, initiate the 
transcriptional atrophy programs leading to autophagy and 
apoptosis, which result in further loss of skeletal muscle 
mass. Because ER stress and UPR are beyond the scope of 
this review, readers are referred to the papers of Cybulsky,21 
Afroze,20 and Bohnert22 for more details.
3 |  IGF‐I/INSULIN‐AKT‐MTOR 
PATHWAY
In the regulation of muscle growth and atrophy, the IGF‐I/
insulin‐Akt‐mTOR pathway is thought to be the main regu-
latory mechanism. This pathway is largely influenced by 
physical activity, nutrition, and various diseased conditions 
(Figures 1, 2).4 The anabolic effects of IGF‐I/insulin on skel-
etal muscle are mediated through specific binding with IRS 
to promote the activation of the phosphoinositide 3‐kinase 
(PI3K)‐Akt‐mTOR signaling pathway. Under normal condi-
tions, IGF‐I/insulin signaling appears to be dominant against 
other catalytic signaling proteins such as myostatin (called 
myokine and inhibitor of myogenesis), and transcription fac-
tors such as FoxO, because the nuclear translocation of FoxO 
and transcription factor EB (TFEB) are inhibited by Akt‐ and 
mTOR‐mediated phosphorylation, respectively (Figure 1). 
However, in case of starvation and critical illness (eg sys-
temic inflammation and cancer cachexia), muscle metabo-
lism represents an adaptive catabolic response characterized 
by enhanced muscle proteolysis and amino acid release to 
sustain liver gluconeogenesis and increased fatty acid oxi-
dation to provide a major energy source by increasing the 
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activity of lipoprotein lipases and the subcellular distribu-
tion of CD36 for fatty acid uptake by skeletal muscle cells.23 
This is caused by decreased IGF‐I/insulin‐Akt‐mTOR sign-
aling and the subsequent translocation of dephosphorylated 
FoxO and TFEB to the nucleus, followed by the enhanced 
transcription of atrogenes and muscle protein degradation 
through the UPS.
Another important factor affecting the IGF‐1/insulin‐Akt‐
mTOR pathway in the regulation of skeletal muscle mass is 
myostatin, an extracellular cytokine (a member of transform-
ing growth factor‐β (TGF‐β) superfamily) mostly expressed 
by skeletal muscle, and a potent negative regulator of muscle 
growth and the activation of satellite cells (stem cells resident 
in skeletal muscle).24 During embryogenesis, myostatin ex-
pression is restricted to the developing skeletal muscles. It is 
still expressed and secreted by skeletal muscles in adulthood, 
playing the roles in inhibiting cell cycle progression and 
reducing levels of myogenic regulatory factors, thereby con-
trolling myoblastic proliferation and differentiation during 
developmental myogenesis. The PI3K‐Akt‐mTOR signaling 
pathway induces hypertrophy of skeletal muscle, which in-
creases the secretion of myostatin, which then controls skel-
etal muscle mass by inhibiting PI3K‐Akt‐mTOR signaling.25 
The role of myostatin in muscle wasting is mediated by activin 
receptor IIB (ActRIIB), which leads to several different sig-
naling cascades. The binding of myostatin to ActRIIB phos-
phorylates the transcription factor smad2/3 complex, leading 
it to form a complex with smad4 (a tumor suppressor), result-
ing in nuclear translocation and blocking of the transcription 
of genes responsible for myogenesis, such as MyoD (Figure 
1). ActRIIB‐mediated myostatin signaling also phosphory-
lates MAPK and activates its downstream cascade leading to 
the downregulation of the myogenesis genes.25 Furthermore, 
myostatin is reported to inhibit Akt signaling by suppressing 
F I G U R E  2  Prolonged skeletal muscle inactivity (disuse). Prolonged muscle disuse leads to nNOS‐mediated muscle atrophy via a FoxO‐
dependent pathway. The stress protein, Grp94, while serving as a chaperone for folding IGFs and antioxidant cytoprotection, functions to stabilize 
subsarcolemmal nNOSµ. AMP/ATP, adenosine monophosphate/adenosine triphosphate; AMPK, AMP‐activated protein kinase; ATGs, autophagy‐
related genes; DGC, dystrophin glycoprotein complex; FoxO, Fork head box O; GRP94, glucose‐regulated protein 94; IGR‐I, insulin‐like growth 
factor‐I; IR/IRS, insulin receptor/ insulin receptor substrate; MAFbx, muscle atrophy F box; mTOR, mammalian target of rapamycin; MuRF‐1, 
muscle ring finger 1; nNOSμ, neuronal nitric oxide synthase μ; NO, nitric oxide; ROS, reactive oxygen species; RyR1, type 1 ryanodine receptor; 
SR, sarcoplasmic reticulum; TFEB, transfactor EB; UPS, ubiquitin proteasome system
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the expression of miR‐486, a positive regulator of the IGF‐I/
Akt pathway, resulting in the upregulation of the atrogenes, 
as shown in an in vitro study 26,27 (Figure 1). Inhibition of 
the myostatin‐ActRIIB pathway results in muscle fiber hy-
pertrophy, which has received much interest as a possible 
therapeutic strategy for a variety of muscle diseases such as 
cancer‐associated cachexia.28
4 |  PROLONGED SKELETAL 
MUSCLE INACTIVITY
Prolonged periods of muscle disuse result in increased ROS 
generation in limb skeletal muscles. Recent evidence sug-
gests that prolonged skeletal muscle inactivity results in in-
creased superoxide production at multiple locations in the 
cells including NADPH oxidase, xanthine oxidase, and in 
the mitochondria.29-33 In particular, the mitochondria are 
thought to be a major source of ROS generation in inac-
tive skeletal muscle.31,32 Furthermore, prolonged inactiv-
ity of limb skeletal muscle is accompanied with increased 
NO levels in the inactive muscle. Unlike in inflammatory 
and cachectic muscles, inducible NOS (iNOS) levels and 
iNOS‐derived NO do not increase in these disused skeletal 
muscles. Rather, Suzuki et al reported that neuronal NOS 
(nNOS) is the source of NO during prolonged skeletal mus-
cle inactivity, suggesting a possible cause and effect rela-
tionship between increased productions of ROS and RNS in 
the disused skeletal muscle.34
The sarcolemmal localization of nNOSµ (a splice vari-
ant of nNOS) by binding to the PDZ domain (postsynaptic 
density protein 95/discs large/ZO‐1 homology domain) of 
α‐syntrophin of the dystrophin glycoprotein complex (DGC) 
is a critical determinant of the physiological vasoregulatory 
effect of skeletal muscle‐derived NO (Figure 2).35 The trans-
location of sarcolemmal nNOSµ to the sarcoplasmic zone has 
been reported to occur in response to various forms of skele-
tal muscle disuse, for example, hindlimb unloading,34,36 space 
flight,37 denervation,34 bed rest,38 and intensive care‐associ-
ated critical illness myopathy.39 Dislocated nNOSµ to the 
sarcoplasma reduces physiological blood flow to the skeletal 
muscle and inappropriately increases cytoplasmic NO avail-
ability, resulting in nitrosations of Akt (which leaves FoxO 
dephosphorylated) and FoxO, both of which accelerate FoxO 
nuclear translocation followed by the enhancement of UPS.40 
In addition, increased cytoplasmic NO also causes hyperni-
trosation of the type 1 ryanodine receptor (RyR1), followed 
by increased Ca2+ leakage from the SR through RyR1 due to 
displacement of calstabin (a stabilizer for the closed state of 
the RyR1 channel).41,42 Therefore, increased cytosolic Ca2+ 
levels cause ROS generation in the mitochondria and activate 
proteases such as calpain and caspases, leading to myofibril-
lar degradation and/or apoptosis (Figure 2).
On the other hand, NO inhibits calpain‐mediated skeletal 
muscle proteolysis via S‐nitrosation of the cysteine residue of 
calpain, as shown in an in vitro study.43,44 In skeletal muscles, 
there are high concentrations of potent NO scavengers includ-
ing myoglobin and glutathione, which could therefore limit 
diffusion‐based NO signaling and localize cGMP‐dependent 
and independent signaling effects in the close vicinity of tar-
get proteins. Whether NO plays a protective or detrimental 
role in muscle mass regulation depends on its quantitative ef-
fect and spatial distribution in the skeletal muscle cells. When 
considering dietary and pharmacological interventions, L‐ar-
ginine or citrulline supplementation as substrates for nNOS 
and eNOS would favorably enhance NOS activity where it is 
normally located.45
Although the detailed mechanism by which skeletal mus-
cle disuse induces dislocation of sarcolemmal nNOSµ to the 
cytoplasm has not yet been elucidated, recent reports have 
shown a novel view point on this mechanism, suggesting that 
glucose‐regulated protein 94 (Grp94), a heat shock protein 
(HSP)/Ca2+ binding chaperone, which is closely associated 
with IGF folding and secretion in skeletal myogenic cells, 
interacts with nNOSμ and stabilizes it by preventing its un-
tethering from the sarcolemma, as well as protecting nNOSμ 
from degradation by UPS.46 Chronic exercise training in mice 
(treadmill training 1 h/d, 5 d/wk for 4 weeks), has been shown 
to significantly increase the muscular levels of Grp94, help-
ing to keep nNOSμ in the sarcolemma.47 However, the mus-
cular levels of Grp94 significantly decrease in the unloaded 
myofibrils, which is associated with enhanced sarcoplasmic 
NO production, and subsequent initiation of the atrophying 
process of skeletal muscle as mentioned above.40,48
The skeletal muscle adapts to the stress of contractile ac-
tivity via changes in gene expression to yield an increased 
content of HSPs, including Grp94. Therefore, reduced stress 
response proteins due to skeletal muscle inactivity might be 
fundamentally related to the initiation of the tissue remodel-
ing processes including muscle atrophy.49
5 |  EXERCISE
5.1 | Exercise leading to mitochondrial 
biogenesis
Exercise is a potent stimulus to preserve skeletal muscle 
mass, aerobic fitness, and strength.50 In skeletal muscle con-
tractions, action potentials generated at the neuromuscular 
junction depolarize rapidly along the surface membrane of 
the muscular fiber, propagating down the transverse tubules 
(T‐tubules) and activate voltage‐gated Ca2+ channels (L‐type 
Ca2+ channels). Voltage‐induced conformational changes 
of L‐type Ca2+ channels activate the closely apposed Ca2+ 
release channel, RyR1, on the terminal cisternae of the SR, 
resulting in a rapid increase in the amount of cytosolic Ca2+, 
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which leads to muscle contraction through the sliding of actin 
and myosin filaments.51
There are two types of exercise that affect the skeletal 
muscle phenotype, endurance and resistance exercise; skel-
etal muscle adapts to the type of exercise by transforming 
the phenotype to include mainly slow or fast twitch fibers.52 
In addition, these two types of exercise are contrary to each 
other in terms of subsequent muscle phenotype expression.53 
Hickson demonstrated that endurance exercise after resis-
tance exercise (endurance + resistance) had detrimental ef-
fects on muscle strength gain compared to resistance exercise 
alone,54 suggesting a training interference between the two, 
which might be caused by some metabolic conversion during 
the exercises.55 Recent studies reported that peroxisome 
proliferator‐activated receptor‐γ coactivator 1α (PGC‐1α) 
plays a very important role in the phenotypic differentiation 
of skeletal muscle. Endurance exercise induces fast to slow 
muscle phenotype transformation, mitochondrial biogenesis, 
and angiogenesis through the AMP‐activated protein kinase 
(AMPK)‐PGC‐1α1 pathway.52 On the other hand, resistance 
exercise stimulates muscle protein synthesis leading to hy-
pertrophy via the Akt‐mTOR‐mediated pathway, which is 
accompanied by the increased expression of PGC‐1α4, an 
alternatively spliced transcript of the PGC‐1α parent gene 
(Figure 3).52,56 A series of studies on this issue suggest that 
there may be a molecular switch mediated by exercise inten-
sity, the so‐called AMPK‐Akt master switch, which partially 
mediates specific adaptations to endurance or resistance 
exercise.57
During endurance exercise, AMPK is allosterically ac-
tivated via an increased AMP/ATP ratio and is phosphor-
ylated via a Ca2+ dependent signaling pathway, followed 
by phosphorylation of PGC‐1α1, and the subsequent ac-
tivation of a number of transcriptional factors associated 
with mitochondrial biogenesis and angiogenesis including 
nuclear respiratory factor 1 and 2 (NRF1/2), peroxisome 
F I G U R E  3  Exercise leads to mitochondrial biogenesis and muscle hypertrophy. Schematic diagram showing the two types of exercise and 
their downstream signaling pathways leading to mitochondriogenesis and muscle hypertrophy. AMP/ATP, adenosine monophosphate/adenosine 
triphosphate; AMPK, AMP‐activated protein kinase; CPT‐1, carnitine palmitoyltransferase 1; CREB1, cAMP response element‐binding protein 
1; DGC, dystrophin glycoprotein complex; eNOS, endothelial nitric oxide synthase; IGF‐I, insulin‐like growth factor‐I; mTOR, mammalian 
target of rapamycin; n/eNOS, neuronal and endothelial nitric oxide synthase; nNOSμ, neuronal nitric oxide synthase μ; NO, nitric oxide; ONOO‐, 
peroxynitrite anion; PGC‐1α, peroxisome proliferator‐activated receptor gamma coactivator‐1α; PI3K, phosphoinositide 3‐kinase; PKA, protein 
kinase A; RyR1, type 1 ryanodine receptor; SR, sarcoplasmic reticulum; TRPV1, transient receptor potential vanilloid subfamily, member 1
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proliferator‐activated receptor (PPARδ), estrogen‐related 
receptor (ERRα), and myocyte enhancer factor 2 (MEF2). 
Activated AMPK also phosphorylates acetyl‐CoA carboxy-
lase (ACC), then reduces the concentration of malonyl‐CoA 
by inhibiting ACC, which in turn reduces the allosteric in-
hibition of carnitine palmitoyltransferase 1 (CPT‐1).58 This 
allows increased rates of fat oxidation following fatty acid 
transport into the mitochondria to provide the major energy 
source in endurance exercise (Figure 3, and in more detail in 
Figure 4).
NO is closely associated with the AMPK‐PGC‐1α1‐me-
diated signaling process by cooperatively modulating muscle 
contraction and oxidative metabolism,59 contributing to the 
mitochondrial biogenesis of skeletal muscle (Figure 4).8 In 
endurance exercise, NO produced by nNOS (and eNOS) not 
only enhances blood flow and oxygen delivery to efficiently 
meet the metabolic demands of active muscle,35 but also 
enhances cGMP‐mediated AMPK activation and PGC‐1α1 
phosphorylation.60 NO‐induced AMPK activation also phos-
phorylates nNOS and eNOS, forming a positive feedback 
activation between AMPK and NOS (Figure 4). A number 
of reports have shown the NO implication in AMPK activa-
tion and subsequent mitochondrial biogenesis.59 Exercise and 
cold temperature‐mediated stimuli to the sympathetic ner-
vous system via β‐adrenergic receptors enhance the transcrip-
tion of PGC‐1α (mainly another alternatively spliced variant 
PGC‐1α4) via the protein kinase A (PKA)/cAMP response 
element‐binding protein 1 (CREB1) pathway (Figure 4).8,61 
In addition, S‐nitrosation of CREB by NO more efficiently 
engages with the promotor of the genes encoding PGC‐1α1, 
exhibiting a stronger transcriptional induction of PGC‐1α1 
(Figure 4). Thus, increased transcription and activation of 
PGC‐1α1 interact with NRF1/2, inducing the expression of 
nucleus‐encoded mitochondrial genes including mitochon-
drial transcription factor A (TFAM) and proteins involved 
in oxidative phosphorylation. PGC‐1α1 also interacts with 
TFAM on mitochondrial DNA (mtDNA) and coactivates the 
transcription of mitochondria‐encoded mitochondrial genes 
(Figure 4).7,8,62
5.2 | Exercise leading to muscle hypertrophy
According to the study by Chen et al,63 AMPK activation 
following exercise is intensity‐dependent; intensities of 
60% VO2max have been consistently reported to induce 
AMPK activation. However, during exercise at intensities 
greater than approximately 60% VO2max, blood glucose 
and muscle glycogen become the primary fuels oxidized to 
produce the ATP required to sustain exercise, resulting in 
an increased reliance on carbohydrates as the predominant 
fuel source. Therefore, high intensity exercise including 
resistance exercise stimulates glycogenolysis, and subse-
quently the Akt‐mTOR pathway, leading to skeletal muscle 
hypertrophy.2
NO is reported to contribute to exercise‐induced muscle 
hypertrophy. Myotubule depolarization induces physiologi-
cal superoxide generation through the activation of NADPH 
oxidase,64 which is localized to the sarcolemma and T‐tu-
bules. The increasing frequency of contractions enhances the 
activity of skeletal muscle NADPH oxidase with increasing 
F I G U R E  4  PGC‐1α, a master 
regulator of mitochondrial biogenesis. 
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superoxide generation. A potential physiological role for this 
process was proposed by Hidalgo et al who suggested that 
the superoxide generated by NADPH oxidase can stimulate 
Ca2+ release from the SR through oxidative modification 
of the RyR1.65 Muscular contraction and exercise generate 
an increased production of ROS and NO.66 Unlike the large 
amount of pathological ROS production by the mitochondria, 
exercise‐induced ROS is primarily of non‐mitochondrial or-
igin, particularly from NADPH oxidase.67,68 The increase 
in intracellular Ca2+ that occurs upon muscle excitation in-
creases nNOS (Ca2+/calmodulin‐activated enzyme) activity 
several fold during contraction. NO and peroxynitrite then 
activate the transient receptor potential vanilloid subfamily, 
member 1 (Trpv1, also known as capsaicin receptor), result-
ing in an increase in the intracellular Ca2+ concentration that 
subsequently triggers activation of the protein kinase mTOR 
(Figure 3).69
One final pathway that modulates skeletal muscle mass 
following exercise involves resistance exercise‐induced mus-
cle hypertrophy via the PGC‐1α4‐mediated pathway. As 
mentioned above, this pathway is thought to be activated by 
resistance exercise‐induced β‐adrenergic stimulation, fol-
lowed by alternative splicing of the PGC‐1α parent gene to 
express PGC‐1α4 rather than PGC‐1α1 (Figure 4).56,70 A 
study by Ruas and his colleagues showed that myotubule 
hypertrophy was induced by treatment with the β‐adrenergic 
agonist with robust hypertrophy accompanied by a 5‐fold in-
crease in endogenous PGC‐1α4 levels and 1.9‐fold increase in 
the protein/DNA ratio. However, no changes were observed 
in PGC‐1α1 levels with β‐adrenergic agonist treatment. 
These results show that PGC‐1α4 is required for myotubule 
hypertrophy in their cellular model.56 Popov et al also sug-
gested that PGC‐1α4 expression may be promoted through 
β2 adrenergic receptor signaling to the alternative promotor 
gene (Figure 4).71 PGC‐1α4 regulates genes in the IGF‐I and 
myostatin pathways (increased and reduced expression of 
IGF‐I and myostatin, respectively), which are well‐known to 
regulate skeletal muscle hypertrophy (Figure 3). Although 
these results are notable, the proposal that skeletal muscle hy-
pertrophy following resistance exercise is mediated through 
PGC‐1α4 remains a matter of debate,72 and requires further 
investigation in future studies.73
5.3 | Therapeutic application of NO 
in skeletal muscle wasting and exercise 
performance
As mentioned above, NO is involved in the regulation of skel-
etal muscle mass; therefore, it is natural to consider the thera-
peutic application of NO in the prevention of skeletal muscle 
wasting. NO is associated with skeletal muscle atrophy in 
muscle disuse, and inflammation and cachexia due to the in-
tracellular spatial arrangement and quantitative effect of NO 
synthesis by dislocated nNOS and cytokine‐activated iNOS, 
respectively.34 Thus far, there has been no report on a thera-
peutic strategy of pharmacological and nutritional NO donors 
to prevent muscle wasting in these conditions. However, re-
active nitrogen intermediates (RNIs) including NO play an 
important role in regulating energy metabolism in skeletal 
muscle mitochondria.74 RNIs and NO elicit cytoprotective 
effects at several levels of the mitochondrial respiratory pro-
cess (eg cytochrome c oxidase and complex I), particularly 
through inhibition of the electron transport chain and subse-
quent ROS production after ischemia‐reperfusion injury.74
On the other hand, exercise induces NO production and 
stimulates NO‐mediated signaling processes leading to mi-
tochondrial biogenesis and skeletal muscle cell hypertrophy. 
Larsen recently showed that dietary nitrate, which is metab-
olized to nitrite, NO, and other RNIs via the enterosalivary 
nitrate‐nitrite‐NO pathway, improves mitochondrial respira-
tory efficiency in human skeletal muscle, which is coupled to 
reduced proton leak across the uncoupling protein‐3 (UCP‐3) 
expressed in the inner mitochondrial membrane and a re-
duction in the expression of adenine nucleotide translocase 
(ANT).74 This oxygen‐sparing effect of dietary nitrate sup-
plementation is associated with reduced oxygen cost during 
exercise, leading to exercise tolerance. These findings have 
been confirmed in many human studies using beetroot juice as 
the source of nitrate,74,75 which may provide a promising nu-
tritional strategy for promoting skeletal muscle performance.
6 |  CONCLUSIONS
Advancing age, low physical activity, malnutrition, inflam-
mation, and cancer‐associated cachexia all account for skel-
etal muscle wasting, which substantially reduces the quality 
of life. In the regulation of skeletal muscle mass, NO is a 
key signaling molecule and plays an important role in skel-
etal muscle physiology because it is tightly linked to many 
relevant pathways (AMPK, PGC‐1α, and PI3K/Akt‐mTOR 
signaling pathways) in the maintenance of both skeletal mus-
cle integrity and proper signaling mechanisms during adapta-
tion to mechanical and metabolic stimulation. On the other 
hand, the inappropriate distribution and increased generation 
of NO due to muscle inactivity and inflammation result in 
the non‐physiological production of ROS and RNS, lead-
ing to the catabolic responses and muscle atrophy via UPS 
and autophagy. When considering NO biology and its thera-
peutic application in the clinical setting, it is important that 
this freely diffusible, highly reactive radical is short‐lived, 
particularly in skeletal muscle where NO scavengers such 
as myoglobin and glutathione are in close vicinity to newly 
generated NO. Therefore, NO bioavailability, whether ben-
eficial or harmful,76 is greatly affected by its concentration 
and distribution. NO bioavailability can depend on how it 
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is administered, such as diet (vegetables rich in nitrate),77 
supplements (nitrite/nitrate, and L‐arginine/citrulline as the 
substrates for NOSs),78,79 and drugs (NO donors).43,59,80,81 As 
it becomes clearer that NO participates in the regulation of 
skeletal muscle mass, future studies should focus on NO‐me-
diated therapeutic applications in health and disease.
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